| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/5000 | Human,Mouse,Rat |
| WB Predicted band size | 39 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Synthetic peptide of human SOX1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇与SOX1抗体相关的文献信息及摘要概括：
1. **文献名称**：*SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome*
**作者**：Sabater L, Titulaer M, Saiz A, et al.
**摘要**：该研究首次发现SOX1抗体可作为副肿瘤性Lambert-Eaton肌无力综合征(LEMS)的生物标志物，尤其在合并小细胞肺癌的患者中阳性率显著，提示其潜在的肿瘤筛查价值。
2. **文献名称**：*SOX1 autoantibodies in patients with paraneoplastic neurological syndromes*
**作者**：Titulaer MJ, Klooster R, Potman M, et al.
**摘要**：通过分析副肿瘤性神经综合征(PNS)患者血清，发现SOX1抗体与肺癌(尤其是小细胞肺癌)相关神经综合征高度相关，建议将其作为肺癌筛查的辅助指标。
3. **文献名称**：*Antibodies to SOX1 and other neuronal antigens in paraneoplastic disorders*
**作者**：Gultekin SH, Dalmau J, Graus Y, et al.
**摘要**：研究揭示了SOX1抗体在副肿瘤性疾病中的特异性表达模式，强调其与Huwey综合征及神经母细胞瘤的关联，并探讨其可能的致病机制。
如需具体研究细节或更多文献，可进一步补充说明需求。
SOX1 antibodies are autoantibodies targeting SOX1. a member of the SOX (SRY-related HMG-box) family of transcription factors. SOX1 plays a critical role in early neurogenesis, particularly in the development and maintenance of neural progenitor cells within the central nervous system. It regulates the differentiation of neurons and glial cells, with expression predominantly observed in the embryonic neural tube and adult neural tissues.
Clinically, SOX1 antibodies are recognized as biomarkers for paraneoplastic neurological syndromes (PNS), especially in association with small cell lung cancer (SCLC). Their presence is strongly linked to Lambert-Eaton myasthenic syndrome (LEMS) and paraneoplastic cerebellar degeneration (PCD). Detection of SOX1 antibodies aids in distinguishing paraneoplastic from non-paraneoplastic neurological disorders, enhancing diagnostic accuracy. While not exclusive to malignancy, their high specificity for SCLC (reported in ~60-70% of LEMS cases) underscores their utility in prompting oncological evaluation.
Testing typically involves indirect immunofluorescence or immunoblot assays using recombinant SOX1 proteins. However, interpretation requires correlation with clinical context, as SOX1 antibodies may coexist with other onconeural antibodies (e.g., anti-Hu, anti-Yo). Research continues to explore their pathogenic role, though current evidence suggests they may serve as epiphenomena rather than direct contributors to neurological damage. Their identification remains a key component in the diagnostic workup of autoimmune neurological disorders with suspected paraneoplastic etiology.
×
